New York Times Company Continues to Thrive Through Strategic Initiatives\n\nThe New York Times Company has once again proven its resilience and strength in the media industry, as it continues to see impressive results through its strategic initiatives. The economic uncertainty, the company has remained a top performer, showcasing its strong fundamentals and attracting attention from industry experts.\n\nIts strategic initiatives, which include digital subscriptions, advertising, and other revenue streams, have been a key factor in the company’s success. The New York Times Company has been able to adapt to the changing media landscape and capitalize on new opportunities, solidifying its position as a leader in the industry.\n\nOne of the company’s most notable achievements is its digital subscription growth. The New York Times Company has seen a significant increase in digital subscribers, with a total of 6.5 million as of October 2021. This not only highlights the company’s strong fundamentals, but also showcases its ability to connect with readers and provide valuable content.\n\nAdditionally, the New York Times Company’s advertising revenue has also seen growth, with a 66% increase in digital advertising revenue in the third quarter of 2021. This is a testament to the company’s ability to attract advertisers and maintain a strong presence in the digital advertising space.\n\nThe company’s success has not gone unnoticed, as industry experts continue to praise its performance.\n\nThe New York Times Company’s strategic initiatives have been a driving force behind its continued success in the media industry.

'Coherus BioSciences Receives FDA Approval for Innovative On-Body Injector for Cancer Treatment Medication\n\nCoherus BioSciences, incorporated (Nasdaq:CHRS) has announced the approval of UDENYCA ONBODY™, an on-body injector for their pegfilgrastim biosimilar, UDENYCA®. This new device provides cancer patients with an automatic delivery option for their medication, reducing the incidence of infection as manifested by febrile neutropenia. The FDA approval was supported by a comprehensive data package, including pharmacokinetic and pharmacodynamic bioequivalence data, as well as adhesive performance and tolerability data.\n\nUDENYCA ONBODY was designed with patients in mind, featuring a five-minute injection time and an innovative retractable needle mechanism. This device is unlike any other on the market, as it was specifically designed for pegfilgrastim administration using proprietary technology and user insights. The approval of UDENYCA ONBODY provides patients and their physicians with another administration option, in addition to the prefilled syringe and autoinjector options already available.\n\nUDENYCA is the only pegfilgrastim brand approved in the United States that offers three administration options, providing patients and healthcare providers with choice, control, and convenience. Since its launch in 2019, over 300,000 patients have been treated with UDENYCA. The commercial availability of UDENYCA ONBODY is expected in the first quarter of 2024.\n\nIn a statement, Coherus CEO Denny Lanfear expressed the company's commitment to providing patients with innovative treatment options, stating, "The on-body injector for UDENYCA is the result of years of significant investment in research and development to bring forward a novel and proprietary device that provides patients with an automatic delivery option for their medication."\n\nUDENYCA ONBODY was designed with patient safety and comfort in mind, featuring an indicator and status light, auditive signal, and a strong and well-tolerated adhesive. After the dose is administered, the needle automatically retracts, reducing the risk of needlestick injury.\n\nThe FDA approval of UDENYCA ONBODY provides cancer patients with another administration option for their medication, further solidifying Coherus BioSciences' position as a leader in innovative immunotherapies for cancer treatment.'